Gsk (GLAXF) Cash from Operations (QoQ) (2009 - 2026)
Gsk (GLAXF) Cash from Operations (QoQ) (2009 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Gsk |
92,316,836.42 Bn |
92,316,831.46 Bn |
7.76 Bn |
| 2 |
Eli Lilly |
983.57 Bn |
978.29 Bn |
16.22 Bn |
| 3 |
Johnson & Johnson |
553.56 Bn |
531.50 Bn |
15.96 Bn |
| 4 |
AbbVie |
383.35 Bn |
374.00 Bn |
10.78 Bn |
| 5 |
Merck |
281.71 Bn |
276.06 Bn |
12.09 Bn |
| 6 |
Amgen |
182.20 Bn |
170.16 Bn |
5.87 Bn |
| 7 |
Gilead Sciences |
153.71 Bn |
145.98 Bn |
5.52 Bn |
| 8 |
Pfizer |
143.75 Bn |
130.98 Bn |
-1.21 Bn |
| 9 |
Bristol Myers Squibb |
109.71 Bn |
99.25 Bn |
8.07 Bn |
| 10 |
Gsk |
- |
- |
7.76 Bn |
| Date | Value |
|---|
| Mar 31, 2026 |
-7.98% |
| Mar 31, 2025 |
-54.01% |
| Mar 31, 2024 |
-39.65% |
| Mar 31, 2023 |
-87.84% |
| Mar 31, 2022 |
55.91% |
| Dec 31, 2021 |
-38.06% |
| Sep 30, 2021 |
95.58% |
| Jun 30, 2021 |
295.66% |
| Mar 31, 2021 |
-90.72% |
| Dec 31, 2020 |
4.30% |
| Sep 28, 2020 |
37.61% |
| Jun 30, 2020 |
177.05% |
| Mar 31, 2020 |
-53.11% |
| Dec 31, 2019 |
-14.94% |
| Sep 30, 2019 |
73.60% |
| Jun 30, 2019 |
107.00% |
| Mar 31, 2019 |
-69.85% |
| Dec 31, 2018 |
5.75% |
| Sep 30, 2018 |
45.90% |
| Jun 30, 2018 |
54.57% |
